Goldline Pharmaceutical IPO
Goldline Pharmaceutical IPO Listing Day Performance
Goldline Pharmaceutical listed on BSE SME on 19 May 2026 at ₹59.75, a 38.95% premium over the issue price of ₹43. A retail investor allotted the minimum application of 6,000 shares (2 lots) gained ₹1,00,500 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹15 (+34.9%) |
| GMP-implied listing | ₹58 |
| Actual listing | ₹59.75 |
| Difference | +₹1.75 (+3.0%) |
Demand going into listing
| Subscribed overall | 840.57× |
| QIB | 180.22× |
| NII | 1662.35× |
| Retail | 880.68× |
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 1.31x | 1.31x | 180.22x |
| NII | 18.07x | 108.19x | 1,662.35x |
| bNII > ₹10L | 24.46x | 146.48x | 1,662.35x |
| sNII 2-10L | 24.46x | 146.48x | 1,662.35x |
| Retail | 34.07x | 139.51x | 880.68x |
| Total | 20.79x | 93.19x | 840.57x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 19.85 | 23.57 | 28.06 |
| Expense | 19.45 | 21.04 | 24.20 |
| Profit (PAT) | 0.26 | 1.81 | 2.83 |
| Total Assets | 19.39 | 22.93 | 26.28 |
Peer Comparison
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Mono Pharmacare Limited | 1.75 | 12.57 | 10 |
| Chandra Bhagat Pharma Limited | 1.14 | 37.73 | 3 |
Promoters & Holding Pattern
Promoters: Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
Strengths & Risks
- Heavily oversubscribed — 840.6x overall (so far).
- Strong institutional (QIB) demand — 180.2x.
- Revenue grew 19% in the latest reported year.
- Solid profit margin — 10.1%.
- Strong return on equity — 36%.
- Elevated leverage — debt/equity of 1.50.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Goldline Pharmaceutical at a glance
From the company's description: “Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline.”
Goldline Pharmaceutical is raising ₹12 crore through an IPO on the BSE SME. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company (₹8.9 crore).
Revenue went from ₹19.85 crore in 2023 to ₹28.06 crore in 2025, up 41% over 2 years. Profit after tax went from ₹0.26 crore to ₹2.83 crore, a net margin of 10% in the latest year.
Debt stands at 1.5 times equity.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Goldline Pharmaceutical Ltd., 103, F-1, Leela Apartment, Shilpa HSG Society,, Near Saptagiri Nagar, Shanidham,, Narendra Nagar,, Nagpur, Maharashtra, 440015
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | 8.90 |
| General Corporate Purpose | - |
Resources & Documents
Anchor Investors
Goldline Pharmaceutical IPO - Quick Take
Goldline Pharmaceutical has set a price band of Rs 41–Rs 43 per share for an issue size of Rs 12 crore. The stock listed with a 38.95% gain versus its issue price on May 19, 2026.
The issue is promoted by Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal with Cumulative Capital Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company (Rs 9 crore) and general Corporate Purpose.
On fundamentals, the company is posting revenue growth of 19.1%, a profit margin of 10.1%, return on equity of 35.8% in its most recent reported period. Listed peers in this segment include Mono Pharmacare Limited (P/E 12.57x, market cap Rs 10 crore) and Chandra Bhagat Pharma Limited (P/E 37.73x, market cap Rs 3 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Goldline Pharmaceutical IPO: Lead Manager & Registrar Track Record
How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Goldline Pharmaceutical itself, so they describe what came before it.
- Goldline Pharmaceutical listed at +39% on day one; the median of 193 listings was +1.5% (better than 84% of them).
- Subscribed 841x against a median of 3.98x across 192 issues (higher than 100%).
- Average listing-day move across all 194 SME listings we track: +11.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Cumulative Capital Pvt. Ltd. Lead manager | 3 2 MB · 1 SME | 100% 3 of 3 | +9.1% | +10% |
| Bigshare Services Pvt. Ltd. Registrar | 61 19 MB · 42 SME | 67% 41 of 61 | Check allotment → | |
Recent listings managed by Cumulative Capital Pvt. Ltd. (3)
Best: Mehul Telecom +10.2% · Weakest: Hexagon Nutrition +7.2%
| IPO | Listed | Listing-day move |
|---|---|---|
| Veegaland Developers | 18 Sep 2026 | +10% |
| Hexagon Nutrition | 12 Jun 2026 | +7.2% |
| Mehul Telecom | 24 Apr 2026 | +10.2% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Goldline Pharmaceutical IPO GMP — What It Means
Its last GMP before listing was 34.9%. Of the 34 SME IPOs we have tracked with a final GMP of 25% or more, 34 listed above, 0 flat and 0 below the issue price; Goldline Pharmaceutical listed 39% above its issue price.
See the full Goldline Pharmaceutical GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Goldline PharmaceuticalNo comments yet. Be the first to share your opinion!